Moderna
MRNA
980 hedge funds and large institutions have $34.9B invested in Moderna in 2022 Q2 according to their latest regulatory filings, with 99 funds opening new positions, 348 increasing their positions, 354 reducing their positions, and 111 closing their positions.
4% more funds holding in top 10
Funds holding in top 10: 23 → 24 (+1)
0.24% less ownership
Funds ownership: 61.71% → 61.47% (-0.24%)
2% less repeat investments, than reductions
Existing positions increased: 348 | Existing positions reduced: 354
2% less call options, than puts
Call options by funds: $2.04B | Put options by funds: $2.07B
3% less funds holding
Funds holding: 1,006 → 980 (-26)
11% less first-time investments, than exits
New positions opened: 99 | Existing positions closed: 111
18% less capital invested
Capital invested by funds: $42.8B → $34.9B (-$7.9B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$581M |
| 2 |
Goldman Sachs
New York
|
+$165M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$139M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$87.2M |
| 5 |
Morgan Stanley
New York
|
+$81.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$671M |
| 2 |
BlackRock
New York
|
-$351M |
| 3 |
Renaissance Technologies
New York
|
-$234M |
| 4 |
D.E. Shaw & Co
New York
|
-$175M |
| 5 |
Coatue Management
New York
|
-$175M |
MRNA Hedge Fund Activity: Q2 2022 in Review
980 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q2 2022, worth a combined $34.9B — down 18% from $42.8B a quarter earlier.
Sellers outnumbered buyers: 111 funds closed out of MRNA and 99 opened new positions — a net loss of 12 holders — while 354 trimmed existing stakes and 348 added.
The largest buyer was Wellington Management Group, adding an estimated $581M. The largest seller was Flagship Pioneering, cutting an estimated $671M.
- 980 institutional investors held Moderna (MRNA) as of Q2 2022, down from 1,006 in Q1 2022.
- Funds reported $34.9B of Moderna stock for Q2 2022, down 18% quarter-over-quarter.
- 99 funds opened new Moderna positions in Q2 2022 and 111 closed out, a net change of -12 holders.
- The largest Moderna buyer in Q2 2022 was Wellington Management Group, an estimated $581M added.
- The largest Moderna seller in Q2 2022 was Flagship Pioneering, an estimated $671M sold.
Based on aggregated 13F filings for Q2 2022.